Mitochondrial DNA exists in many copies per cell, and when different mitochondrial genomes coexist the condition is called heteroplasmy. Over a human lifetime the proportion of mutant to wild-type mitochondrial genomes shifts because of both inherited variation and new, somatic changes. These shifts are important for disease risk, aging phenotypes, and population differences in mitochondrial function.
Mechanisms driving shifts
Two principal processes explain age-related changes: transmission dynamics after conception and ongoing somatic mutation. The mitochondrial bottleneck during oogenesis concentrates or dilutes maternal variants, setting an initial heteroplasmy level for each individual. Patrick F. Chinnery at the University of Cambridge has documented how inherited heteroplasmies can vary widely between siblings and tissues, influencing later phenotypes. During life, somatic mutation accumulation and clonal expansion alter heteroplasmy. Douglas C. Wallace at the University of Pennsylvania and colleagues have described how replication errors, oxidative damage, and selection on mitochondria lead some mutant genomes to rise in frequency within a tissue, especially when cells are long-lived and replicate mitochondria many times.
Tissue-specific patterns and consequences
Different tissues show distinct trajectories. Rapidly renewing tissues such as blood often display lower and more variable heteroplasmy because cell turnover dilutes mutated genomes, whereas post-mitotic tissues like skeletal muscle and brain commonly accumulate higher levels of deleterious variants with age. Analyses from the Genotype-Tissue Expression project at the National Institutes of Health and related large sequencing efforts have shown that heteroplasmic variants detected in blood may not reflect levels in heart, brain, or muscle, making interpretation of clinical tests context-dependent. High heteroplasmy in energetically demanding tissues can impair oxidative phosphorylation, contributing to myopathy, neurodegeneration, or age-related decline; Patrick F. Chinnery at the University of Cambridge has linked such patterns to clinical presentations in mitochondrial disease cohorts.
Environmental and cultural factors shape this landscape. Lifestyle exposures such as smoking, certain medications, and regional differences in diet or infectious burden can modulate oxidative stress and selection on mitochondria, altering heteroplasmy dynamics. Population-level differences in mitochondrial haplogroups described by Douglas C. Wallace at the University of Pennsylvania also set baseline variation that interacts with age-related change.
Understanding how heteroplasmy shifts across tissues with age is therefore crucial for interpreting genetic tests, assessing disease risk, and designing interventions such as mitochondrial replacement or targeted therapies; outcomes remain sensitive to tissue sampling, individual history, and population background.